Publication Name	World Journal of Gastroenterology
Manuscript ID	19821
Country	United States

Received	2015-05-22 16:32
Peer-Review Started	2015-05-23 15:14
To Make the First Decision	2015-09-29 13:52
Return for Revision	2015-09-30 09:28
Revised	2015-10-29 20:52
Second Decision	2015-11-10 08:44
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-11-19 13:25
Articles in Press	2015-11-19 13:25
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-01-06 18:05
Publish the Manuscript Online	2016-01-20 16:55

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Frontier
Article Title	Molecular genetics and targeted therapeutics in biliary tract carcinoma
Manuscript Source	Invited Manuscript
All Author List	Eric I Marks and Nelson S Yee
Funding Agency and Grant Number
Corresponding Author	Nelson S Yee, MD, PhD, Program of Experimental Therapeutics, Penn State Hershey Cancer Institute, 500 University Drive, Hershey, PA 17033-0850, United State. nyee@hmc.psu.edu
Key Words	Biliary tract carcinoma; Cholangiocarcinoma; Gallbladder carcinoma; Molecular genetics; Personalized treatment; Precision therapy; Targeted therapy
Core Tip	For patients with cholangiocarcinoma and gallbladder carcinoma, targeted therapeutics provide new opportunity of treatment that is potentially less toxic and more effective. These target-specific monoclonal antibodies and small molecule inhibitors are directed against the signaling pathways that drive the progression of biliary tract cancers. This article provides an updated review of the molecular pathogenesis of these malignant neoplasms as the framework for describing the mechanisms by which targeted agents work. The preclinical and clinical data from investigation of targeted therapeutics in biliary tract cancer are discussed.
Publish Date	2016-01-20 16:55
Citation	Marks EI, Yee NS. Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol 2016; 22(4): 1335-1347
URL	http://www.wjgnet.com/1007-9327/full/v22/i4/1335.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i4.1335

Full Article (PDF)	WJG-22-1335.pdf
Full Article (Word)	WJG-22-1335.doc
Manuscript File	19821-Review.docx
Answering Reviewers	19821-Answering reviewers.pdf
Audio Core Tip	19821-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	19821-Conflict-of-interest statement.pdf
Copyright License Agreement	19821-Copyright assignment.pdf
Peer-review Report	19821-Peer-review(s).pdf
Scientific Misconduct Check	19821-Scientific misconduct check.pdf
Scientific Editor Work List	19821-Scientific editor work list.pdf